C urrently, T cells dedicated to mediating immunosuppression and homeostasis are called regulatory T (Treg) cells. Treg cells are closely associated with infection, allergy, autoimmunity, tumor immunity, fetal-maternal tolerance, and organ transplantation. Treg cells exert their immunosuppressive functions by directly killing or inhibiting T cells and antigen-presenting cells (dendritic cells, macrophages, and B cells) and by producing suppressive cytokines such as TGF-b, IL-10, IL-35, and galectin-1. However, the classification and phenotypes of Treg cell subsets remain largely unclear. The discovery of tissue-resident Treg cells with transcriptional, phenotypic, and functional heterogeneity renders Treg cell subsets more enigmatic. Research regarding tissue-resident Treg cells has become a hot topic. Due to the particular distribution, distinct developmental process and antigenic specificity of various tissue-resident Treg cells, their roles also go beyond the canonical functions of the immune system in health and disease 1,2 . The best example is the visceral adipose tissue Treg (VAT-Treg) cell subset, which prevents obesity-associated inflammation and preserves insulin sensitivity and glucose tolerance; thus, this subset of cells is closely associated with obesity, type 2 diabetes and metabolic cardiovascular disease 3, 4 . In a recent issue of Nature Immunology, Vasanthakumar et al. revealed a critical role and mechanism of the IL-33/ST2 axis in the development and maintenance of VAT-Treg cells 5 . The classification and phenotypes of Treg cell subsets are extremely complex and confusing. Listing all of the subsets that have been discussed in the literature is difficult. To recognize VAT-Treg cells better, the following basic information regarding how to group Treg cell subsets that have frequently appeared in published papers must be understood (Table 1) In the second approach (Figure 1b) , wild-type (WT), ST2-deficient (Il1rl1
) and IRF4-deficient (Irf4 2/2 ) mice were used to reveal the crucial roles of these molecules in VAT-Treg cell development and how PPAR-c and ST2 expression was upregulated. IL-33 is known to signal through the adaptor protein MyD88, while IRF4 and BATF are T cell-associated transcriptional regulators. Compared to WT mice, the deficiencies of ST2, IL-33, Myd88, BATE, and IRF4 greatly reduced VAT-Treg cells, while the numbers of cTreg or eTreg cells in spleen, lymph nodes, and some other tissues were moderately affected or unaffected. Sufficient and convincing data have demonstrated that (i) the IL-33/ST2 axis is specifically required for VAT-Treg cell proliferation and differentiation both in vitro and in vivo, (ii) VAT-Treg cell differentiation requires MyD88-mediated signaling downstream of IL-33, and (iii) BATF and IRF4 are indispensable transcriptional regulators for VAT-Treg cells to express PPAR-c and ST2. As outlined in Figure 2 , TCR stimulation via a specific antigen in vivo or via anti-CD3/anti-CD28 in vitro induced BATF and IRF4 expression, which triggered PPAR-c and ST2 expression by simultaneously binding Pparg (encoding PPAR-c) and Il1rl1 (encoding ST2) loci. The requirement for TCR signalling in VAT-Treg cell development was also confirmed by detecting the expression of Nur77 and TCF7, two transcription factors that are up-and downregulated, respectively, in response to TCR signaling.
In the third approach (Figure 1c) , the crucial role of IL-33 in VAT-Treg cell development and maintenance was further tested by IL-33 administration into New Zealand obese (NZO, genetically obese) mice and high fat diet-induced obese mice (HFD mice). Compared to control C57BL/6 mice, NZO mice displayed early onset of obesity and hyperglycemia, as well as severely reduced numbers of VAT-Treg cells 14, 15 . The VAT-Treg cells from NZO mice expressed extremely low levels of ST2 and KLRG1. Compared to control mice fed with normal chow, HFD mice also displayed a reduced number of VAT-Treg cells and abnormal metabolic parameters. IL-33 administration in NZO and HFD mice rescued VAT-Treg cell numbers, restored ST2 and KLRG1 expression on NZO VAT-Treg cells, improved metabolic parameters including fasting blood glucose concentration and glucose tolerance, decreased VAT mass and adipocyte size, and suppressed the obesity-associated inflammation in VAT with reduced VAT proinflammatory monocytes, macrophages, and CD8 1 T cells. However, IL-33 administration did not affect insulin sensitivity in NZO and HFD mice.
Taken together, the three approaches outlined above demonstrate that the IL-33/ST2 axis plays an essential role in the development of VAT-Treg cells in both the mouse and human. These findings provide new insight into the differential mechanism of specialized Treg cell subsets. Thus, IL-33 has potential future uses in treating obesity and obesityassociated metabolic cardiovascular , BATF-deficient; Irf4 2/2 , IRF4-deficient; NZO; New Zealand obese; Chow, fed with normal chow; HFD, high fat diet-induced obese mouse. *A&D molecules, activation-and differentiation-associated molecules; GzmB, granzyme B; SP, spleen; LN, lymph nodes; CD39, ectonucleotidase; Tigit, co-inhibitory molecule.
diseases. Further studies are required to determine the triggers of cTreg or eTreg cell migration into adipose tissue. The antigenic specificity of VAT-Treg cells remains to be further investigated. In addition, clarifying the causality between obesity and the reduced Treg cell number in adipose tissue and uncovering the underlying mechanisms are important. Whether obesity-associated inflammation results in the reduced VATTreg cell number in adipose tissue or whether the reduction of VAT-Treg cell number causes the obesity-associated inflammation remains to be determined. 
